Recent News

• 07.30.2026 - Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
• 07.21.2026 - Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
• 07.07.2026 - U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
• 06.29.2026 - Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
• 06.13.2026 - Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
• 06.01.2026 - Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
• 05.29.2026 - Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
• 05.22.2026 - Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
• 05.12.2026 - Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
• 05.12.2026 - Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

Recent Filings

• 07.30.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.30.2026 - 8-K Current report
• 07.30.2026 - EX-99.1 EX-99.1
• 07.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.02.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2026 - 144 Report of proposed sale of securities
• 06.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.23.2026 - 4 Statement of changes in beneficial ownership of securities